Landauer Inc

Landauer — Investor Presentation (May 2016)

24 slides from Landauer's investor presentation, May 13, 2016

  1. Slide 1: Investor Presentation February 2016

    Investor Presentation February 2016

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statemen Some of the information shared here (including, in particular, the section titled “Fiscal 2016 Outlook”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptio

  3. Slide 3: Compelling Investment Opportunity

    3 Compelling Investment Opportunity Industry leading position, compelling market trends and strong financial profile drives long-term shareholder value •The Joint Commission standards effective in July 2015 in the United States -Impacts 7,100 of the 20,500 U.S. healthcare organizations and programs,

  4. Slide 4: Leading OSL Technology Supported by Proven Process

    Dosimetry Reports with results are made available to the customer 4 Leading OSL Technology Supported by Proven Process .“Gold standard” in accuracy .Proprietary OSL crystal technology manufactured internally .Delivers wide-range of radiation monitoring: .Headquartered in Glenwood, IL .650 global emp

  5. Slide 5: Serving Diverse End Markets Across Three Verticals

    5 Serving Diverse End Markets Across Three Verticals Acute Care Hospitals Professional Offices Industrial Energy Emergency Response Military/ National Security/DOE W:\Landauer\Investors\Investor deck\Images\73470968_5.jpgW:\Landauer\Investors\Investor deck\Images\L41513.2429.jpgPhysician Offices IDN

  6. Slide 6: Strong Global Footprint

    6 Strong Global Footprint Well-positioned to serve an expanding global customer base of ~75,000 clients Service Labs Chicago Mexico Brazil Paris Istanbul Beijing Tokyo Australia

  7. Slide 7: Significant International Growth Opportunity

    7 Significant International Growth Opportunity 80% 20% FY GAAP 2015 Revenue Domestic U.S.InternationalAdditional $2.3 million in Equity Income from International Joint Ventures Joint Venture Location Nagase-Landauer Japan Epsilon Landauer Turkey Aquila New Mexico Estimated 25% international market s

  8. Slide 8: U.S. Healthcare Trends are Fueling Opportunity

    8 U.S. Healthcare Trends are Fueling Opportunity Increasingly complex and multi-dimensional radiation management landscape creates need for integrated, enterprise-wide solutions Risk to Health SystemsTougher State Regulations Emerging •Pennsylvania •California •Massachusetts •Rhode Island •Texas Hea

  9. Slide 9: Uniquely Positioned to Capitalize on Demand for Solutions

    Reports: Necessary for compliance Analytics: Context to information Benchmarking: Relevance to peers Training: Assures compliance and patient outcomes Continuous Improvement: Integrated data across the enterprise 9 Uniquely Positioned to Capitalize on Demand for Solutions Combining products, service

  10. Slide 10: Strategic Path Forward

    10 Strategic Path Forward .Shift the market focus .Simple dose focus . Continuous management of radiation safety .Better equip customers to monitor and control employee exposure and meet increasing compliance regulations .Leverage digital-based platform to grow offering of tailored products and serv

  11. Slide 11: Verifii: Redefining Our Core Technology

    11 Verifii™: Redefining Our Core Technology .Provides customers with a scalable, digital platform that connects employees to their environment .Eliminates fragmented manual processes enabling focus on building a robust radiation management solution .Timely radiation data adds value to customers by a

  12. Slide 12: Creating a New Standard with Digital Dosimetry

    12 Creating a New Standard with Digital Dosimetry Real-time and historic data & analytics are available to client via web & mobile apps Data is processed and stored in the cloud Dosimeter connects via Bluetooth LE to docking base station Dosimeter is assigned to individual onsite; establishing chain

  13. Slide 13: Significant Opportunities Across Core Verticals

    13 Significant Opportunities Across Core Verticals .Virtual compliance solution for smaller offices that do not have an existing function in place .340,000 sites across Veterinarians, Medical, Dental and Chiropractic practices .6% estimated U.S. market share .Increasing regulations and use of advanc

  14. Slide 14: Strong Recurring Revenue Base

    14 Strong Recurring Revenue Base $138 (91%) $136 (91%) $137 (88%) $139 (92%) $14 $14 $18 $13 $0$20$40$60$80$100$120$140$160$1802012201320142015Revenue ($ in millions, FYE 9/30) Recurring RevenueNon-Recurring Revenue$152 $150 $155 $151

  15. Slide 15: Balanced Approach to Capital Allocation

    15 Balanced Approach to Capital Allocation .Core business investments focused on top and bottom line growth .Emphasis on higher margin, annuity-style opportunities .Commercialization of next generation digital dosimetry platform while transitioning from current OSL crystal-based platform .Management

  16. Slide 16: Compelling Investment Opportunity

    16 Compelling Investment Opportunity Industry leading position, compelling market trends and strong financial profile drives long-term shareholder value •The Joint Commission standards effective in July 2015 in the United States -Impacts 7,100 of the 20,500 U.S. healthcare organizations and programs

  17. Slide 17: Financial Overview

    Financial Overview

  18. Slide 18: Landauer Financial Overview

    18 Landauer Financial Overview $152.1 $149.7 $155.1 $151.3 2012201320142015Revenue ($ in millions, FYE 9/30) .Approximately 90% of revenue derived from subscriptions and is recurring in nature .Increase operating income at a higher growth rate than revenue .Contract with U.S. Army, Reserve and Natio

  19. Slide 19: Key Q1 FY 2016 Financial Drivers

    Key Q1 FY 2016 Financial Drivers .Revenue of $36.5 million in the first quarter of fiscal 2016 down $1 million y/y due to unfavorable FX and our divested Radon business .Domestic Radiation Measurement service revenues grew by 2.8% over the prior year period .Medical Physics revenues grew 10.6% over

  20. Slide 20: Q1 FY2016 Adjusted Results

    20 Q1 FY2016 Adjusted Results ($ Millions) Q1 FY2016 As Reported Non-cash Stock Based Compensation Reorganization, Divestiture and Transaction Expenses Q1 FY2016 Adjusted Revenue $36.5 - $36.5 Net Income $3.6 $0.4 $0.1 $4.1 Adjusted EBITDA* $8.9 $0.5 $0.2 $9.6 *Non-GAAP financial measure

  21. Slide 21: Fiscal Year 2016 Outlook

    .We expect the adverse impact of FX to reduce y/y revenue by $2.9 million and adjusted net income by $0.4 million Fiscal Year 2016 Outlook 21 Fiscal Year 2016 Outlook ($ Millions) Fiscal Year 2015 Actual Adjustment for FY2015 Divestiture FY 2015 Excluding Divested Business Fiscal Year 2016 Guidance

  22. Slide 22: Appendix

    Appendix

  23. Slide 23: Landauer at a Glance

    Business Facts Proven Technology Platform Fiscal 2015 Financial Highlights Diverse Markets .$151.3 Million in Annual Revenue .$30.5 Million in International Sales .~ 90% Recurring Revenues .$40.6 Million in Adjusted EBITDA .Adjusted EBITDA margin 26.8% .Headquartered in Glenwood, IL .Founded in 1954

  24. Slide 24: Adjusted EBITDA definition

    Adjusted EBITDA is presented here not as an alternative to net income, but rather as a measure of the Company’s operating performance and is not intended to be a presentation in accordance with GAAP. Since EBITDA (generally, net income plus interest expenses, taxes, depreciation and amortization) is

Landauer — Investor Presentation (May 2016) on 6ix